12 recruiting, 4 completed, 3 not yet recruiting, 3 unknown. 24 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 24 | Recruiting 12, Completed 4, Not yet recruiting 3, Unknown 3, Active not recruiting 1, Terminated 1 |
| Phase 2 | 5 | Recruiting 3, Not yet recruiting 1, Unknown 1 |
Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Primary Radiotherapy In MEtastatic Lung Cancer Radiotherapy followed by chemotherapy, Standard of Care (SOC) - Carcinoma, Non-Small-Cell Lung (NSCLC) | Phase 3 | Recruiting | Trans Tasman Radiation Oncology Group | 420 | 2026-10-30 | 2026-10-23 |
| Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS short-course radiotherapy, Serplulimab, CapOx(Capecitabine+ Oxaliplatin) - Locally Advanced Colon Cancer, pMMR | Phase 3 | Not yet recruiting | Fudan University | 480 | 2026-10-15 | 2026-10-16 |
| A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer standard EBRT+Brachytherapy, Cisplatin, Neoadjuvant chemoimmunotherapy - Locally Advanced Cervical Carcinoma | Phase 3 | Not yet recruiting | Fujian Cancer Hospital | 486 | 2026-09-01 | 2026-05-29 |
| Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC Short-course radiotherapy, Long-course radiotherapy, Immunotherapy - Locally Advanced Rectal Adenocarcinoma, Neoadjuvant Chemoradiation | Phase 2 / Phase 3 | Not yet recruiting | Beijing Friendship Hospital | 342 | 2026-07-15 | 2026-06-17 |
| HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven) Procedure (FOLFOX-HAIC): Max 4 cycles within first 16 weeks., TACE (transarterial chemoembolization) combined with targeted/immunotherapy - Hepatocellular Carcinoma | Phase 3 | Recruiting | Binkui Li | 300 | 2026-05-15 | 2026-05-22 |
| A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide) - Melanoma (Skin Cancer), Melanoma Stage IIIB-IV | Phase 2 / Phase 3 | Recruiting | Linnaeus Therapeutics, Inc. | 135 | 2025-08-06 | 2026-04-22 |
| Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer Electroacupuncture combined with immunotherapy, Zilongjin tablet combined with immunotherapy, Immunotherapy - Non-Small Cell Lung Cancer, Electroacupuncture | Phase 2 / Phase 3 | Recruiting | Kong Fanming | 405 | 2025-01-01 | 2025-06-24 |
| TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC Immunotherapy, chemotherapy: Paclitaxel/Cisplatin or other guideline recommended regimens, TDLN-sparing RT - Esophageal Carcinoma, Radiotherapy | Phase 3 | Recruiting | Fudan University | 432 | 2024-11-01 | 2026-01-07 |
| Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer Stereotactic Body Radiotherapy, second-line systemic therapy - Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV | Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 104 | 2024-09-01 | 2024-08-30 |
| Adjuvant vs Surgery Only in Early-stage Recurrent NPC Immunotherapy,Toripalimab Injection, Chemotherapy,Gemcitabine based regimen - Recurrent Nasopharyngeal Carcinoma | Phase 3 | Recruiting | Eye & ENT Hospital of Fudan University | 176 | 2024-06-25 | 2025-07-04 |
| Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma Chemotherapy, Immunotherapy (Pembrolizumab), radiotherapy - Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Recruiting | Peking Union Medical College Hospital | 120 | 2024-01-12 | 2025-04-02 |
| A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor. Palliative Radiotherapy, Chemotherapy, Hormone therapy - Metastatic Tumor | Phase 3 | Recruiting | David Palma | 180 | 2023-10-06 | 2025-12-31 |
| Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy radiotherapy, Platinum-Based Drug, Immunotherapy - Non-small Cell Lung Cancer Stage III | Phase 3 | Unknown | Zhejiang Cancer Hospital | 105 | 2023-09-15 | 2023-09-13 |
| Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma Dendritic cell + Cytokine-induced killer cell (DC+CIK) immunotherapy, Tegafur Only Product - Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor | Phase 2 / Phase 3 | Unknown | University of Malaya | 52 | 2023-01-03 | 2024-01-10 |
| Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy SRT, Immunotherapy - Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer | Phase 3 | Unknown | Institut Cancerologie de l'Ouest | 112 | 2022-01-12 | 2023-02-21 |
| Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021) the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors. - Acute Lymphoblastic Leukemia, Pediatric, ALL, Infants | Phase 3 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 80 | 2021-09-23 | 2024-06-28 |
| Documentation of Efficacy of Intralymphatic Allergen Immunotherapy Grass pollen extract - Alutard Phleum pratense, ALK - Allergic Rhinitis Due to Grass Pollen, Allergic Conjunctivitis of Both Eyes | Phase 3 | Completed | Aarhus University Hospital | 450 | 2020-02-01 | 2025-08-12 |
| Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors Palliative Radiation, Chemotherapy, Immunotherapy - Metastatic Tumors | Phase 3 | Active not recruiting | David Palma | 204 | 2019-02-22 | 2026-09-30 |
| Traditional Complementary and Alternative Medicine (CAM) Therapy in the Treatment of HIV/AIDS "Kallunk oxide (Immunotherapy) " - HIV Infections | Phase 3 | Completed | Traditional Alternative Medicine Research, India | 1000 | 2012-02-27 | 2017-03-03 |
| Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Olea Europaea Pollen Immunotherapy with modified extract of Olea europaea pollen, Placebo - Rhinitis or Rhinoconjunctivitis With or Without Asthma Induced by Hypersensitivity to Olea Europea Pollen | Phase 3 | Completed | Laboratorios Leti, S.L. | 158 | 2008-01-01 | 2018-02-23 |
Showing 20 of 24. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (5) · Neoplasm Metastasis (4) · Esophageal Neoplasms (3) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Colonic Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · HIV Infections (1) · Hypersensitivity (1) · Lung Neoplasms (1) · Melanoma (1) · Nasopharyngeal Carcinoma (1) · Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Prostatic Neoplasms (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · David Palma (2) · Fudan University (2) · Laboratorios Leti, S.L. (2) · Aarhus University Hospital (1) · Beijing Friendship Hospital (1) · Binkui Li (1) · Cell Genesys (1) · Eye & ENT Hospital of Fudan University (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Fujian Cancer Hospital (1) · Institut Cancerologie de l'Ouest (1) · Kong Fanming (1) · Linnaeus Therapeutics, Inc. (1) · Peking Union Medical College Hospital (1)
China (10) · Canada (3) · Australia (2) · France (2) · Netherlands (2) · Spain (2) · Sweden (2) · Switzerland (2) · United Kingdom (2) · United States (2) · Belgium (1) · Denmark (1) · Germany (1) · India (1) · Malaysia (1)
Binkui Li (1) · David Palma, MD (1) · Fuming Qiu, PhD (1) · Hongmeng Yu (1) · Johannes M Schmid, MD PhD (1) · Juan Luis Anguita, MD (1) · Pedro Guardia, MD (1) · Ramakrishnan Madhusoodanan, PHD (1) · Robert Olson, MD (1) · Sanjun Cai, MD (1) · Shankar Siva (1) · Stephen Harrow, MB ChB (1) · Suresh Senan, MRCP, FRCR (1) · Xu Yujin, PhD (1) · Zhen Zhang, MD (1)
PMID 23740935, PMID 31426760, PMID 33608212, PMID 39244532, PMID 40367097, PMID 40953876